EGCG Pre-emptive Priming for Scar Quality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current scar management strategies often result in suboptimal scarring outcomes, particularly for hypertrophic and keloid scars, which can be challenging to treat and may have a significant physical and psychological impact on individuals.
Innovation Solution
The use of (-)-epigallocatechin-3-gallate (EGCG) as a topical agent for pre-emptive priming of the skin at potential surgical sites, applied at least 3 days prior to surgery, to enhance scar quality and reduce the risk of abnormal scarring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical treatment is delayed until after wound healing and scar formation, then the treatment can be applied to established scars, but the scar quality outcome is suboptimal and abnormal scarring may have already occurred
Solution Approach 1:
The patent applies EGCG topical treatment pre-emptively before surgical injury occurs, rather than waiting for wound healing or scar formation. This preliminary action modifies the skin's healing response in advance, preventing abnormal scarring before it can develop, thereby achieving superior scar quality outcomes without time delay.
Solution Approach 2:
The patent uses EGCG to prevent mast cell activation and excessive inflammation before injury occurs. This preliminary anti-action counteracts the harmful effects that would normally drive abnormal scarring, thereby improving scar quality by preventing the problematic processes before they can occur.
2Ease of manufacture
If conventional scar management is used, then treatment can be applied to existing scars, but hypertrophic and keloid scars may develop and are difficult to manage
Solution Approach 1:
The patent applies EGCG treatment before surgery to pre-emptively modify the skin's healing response. This preliminary action prevents mast cell activation and excessive inflammation that would otherwise lead to hypertrophic and keloid scarring, making scar management easier by preventing difficult-to-treat scar types before they develop.
Solution Approach 2:
The patent converts the potentially harmful inflammatory response that leads to abnormal scarring into a beneficial controlled response. By applying EGCG pre-emptively, the treatment transforms what would be harmful mast cell activation into a regulated process, preventing hypertrophic and keloid scar formation while maintaining normal healing functions.
3Manufacturing precision
If immediate topical application is made at the zone of injury, then scar thickness and angiogenesis are reduced, but the treatment must be applied precisely at the optimal time which is counterintuitive to conventional practice
Solution Approach 1:
The patent applies EGCG treatment before surgery rather than at the time of injury or after scar formation. This preliminary action allows the treatment to be implemented easily in advance of the surgical procedure, eliminating the need for precise timing at the moment of injury while still achieving the desired reduction in scar thickness and angiogenesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Pre-emptive priming with EGCG significantly reduces mast cell numbers, angiogenesis, and scar thickness while increasing elastin content, leading to improved cosmetic outcomes and a reduced risk of hypertrophic or keloid scars.
Implementation Method 1
Catechins are a family of phenolic compounds, naturally occurring in plants, such as green and black tea, which have been shown to have antioxidant, anti-inflammatory, antiangiogenic, antiallergic, and antimicrobial effects.
Implementation Method 2
Catechins are a family of phenolic compounds, naturally occurring in plants, such as green and black tea, which have been shown to have antioxidant, anti-inflammatory, antiangiogenic, antiallergic, and antimicrobial effects.
Implementation Method 3
Pre-emptive priming with EGCG significantly reduces mast cell numbers, angiogenesis, and scar thickness while increasing elastin content
Implementation Method 4
Catechins are a family of phenolic compounds, naturally occurring in plants, such as green and black tea, which have been shown to have antioxidant, anti-inflammatory, antiangiogenic, antiallergic, and antimicrobial effects.
Data Source
Figure 1
Figure 1
Figure 2
AI summary
A method of enhancing the quality of a skin scar by topical application of an agent for improving scar quality is characterised in that said agent is pre-emptively applied to a potential surgical cutaneous site in advance of surgery, including surgery involving use of lasers. The topical agent may be a polyphenol, such as (-)-epigallocatechin-3-gallate (EGCG). Use of such a topical agent in advance of surgery leads to significant beneficial effects on dermal scarring by reducing mast cells, angiogenesis, skin thickness and simultaneously increasing elastin content. The topical agent may be applied directly or incorporated in a dressing, such as in a dermal patch comprising an adhesive silicone sheet, and can be worn both in the lead up to surgery and post-operatively.